Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer's Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
There has been much debate of how the capital market landscape is looking to shape up for bioscience companies with the impending implementation of the JOBS Act. However, even greater debate rages as to what the landscape will look like after the provisions are put into effect. One t
The Contrast Induced Kidney market is a large one, at about $500 million. This is due to the fact that Acute Kidney Injury affects 3-7% of all patients admitted into hospitals and about 25-30% of patients admitted into the Intensive Care Unit. Complexa's technology has the potential t
GreeneStone Healthcare Corp. (OTCBB: GRST) operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly under-serviced niches. Greenestone President and CEO Shawn Leon sp
Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivi